Bringing exquisite precision to gene expression.
Our small molecule inhibitors work by breaking apart this complex of proteins, enabling meticulous control over gene expression in the cancer cell.
We aim to bring exquisite precision by harnessing the power of transcription factors and controlling gene programs that are relevant to human cancers. This molecular strategy embraces our unique approach to transcription factors, where our small molecules target abnormal SOX18 function, switching off key processes that drive cancer growth and spread in patients.
SOX18 – Out like a light
Our small molecule inhibitors target the area of SOX18 that helps form the complexes, to manipulate multiple hallmarks of cancer cell functions.
This disrupts the growth and spread of cancer, switching it off.
Major market potential
Gertrude’s drug development program and the multi-functional nature of SOX18 is lighting the way towards the larger oncology market, offering significant commercial and clinical potential.
Collaborative and investigational work to date shows promising data across a range of large drug markets, in areas with identified treatment shortfall and unmet clinical needs.
Why we shine
Gertrude’s molecular strategy brings exquisite precision to the science of transcription factors, that control genetic programs contributing to the hallmarks of human cancers. By using small molecules to control this process, we believe our approach may offer greater potential than current therapeutics to ‘drug the undruggable’.
Our Partnerships and collaborations
Our biology and medicinal chemistry teams have collaborated with local and international experts in the field to build a growing body of evidence relating to the role of SOX18 and its inhibitor approach in cancer. This includes independent validations and the publishing of papers.
Gertrude continues to seek partnership and collaborative opportunities to drive momentum in developing transformational solutions to untreatable cancers.